Healthcare
LivaNova PLC(LIVN)
Live Price
Offline$78.50
+0.00% today
1Y Change
+71.53%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $3.33B
- Revenue Growth
- +10.7%
- EPS Growth
- -480.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
LivaNova PLC (LIVN) is a Healthcare stock with a market cap of $3.33B and listed on NASDAQ. The stock last traded around $78.50 and up 71.5% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +10.7%, EPS growth of -480.3%, a dividend yield of 0.0%. What stands out right now is revenue +10.7%, EPS -480.3%, free cash flow +27.4% with operating margin 14.4% and ROIC 10.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LIVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.7% vs +7.6% peer median
Operating Margin
Below sector median
+14.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +10.7% and EPS is at -480.3%, with operating margin around 14.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +7.0% | +9.3% | +11.3% |
2026 Feb 25, 2026 | +7.5% | +1.0% | -7.2% | -9.9% |
2025 Nov 5, 2025 | +20.8% | -2.4% | +11.4% | +25.8% |
Benchmark Edge
LIVN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LIVN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LIVN Max Drawdown
-18.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LIVN and SPY.
Company Overview
LivaNova PLC
NASDAQ Global Select
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
- Leadership
- Vladimir A. Makatsaria
- IPO Date
- Oct 19, 2015
- Employees
- 2.9k
- Street Address
- 20 Eastbourne Terrace
- Mailing
- London, W2 6LG
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 3325 0660
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.4
- Price/Book
- 2.8
Growth
- Revenue
- +10.7%
- EPS
- -480.3%
- Free Cash Flow
- +27.4%
Profitability
- Gross Margin
- 68.0%
- Operating Margin
- 14.4%
- Net Margin
- -17.5%
- ROE
- -21.5%
- ROIC
- 10.9%
Balance Sheet
- Debt/Equity
- 0.39
- Current Ratio
- 1.36
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.